By Sabela Ojea


Merck & Co. said Thursday that a West Virginia district court ruled in favor of the company in a two-patent infringement suit against Viatris Inc.

The company said that the case was related to the sitagliptin medication, which is mainly sold under the brand names Januvia and Janumet to treat type 2 diabetes.

The federal court found both Merck's patents involved on the case were valid and infringed, Merck said, noting that the decision is still subject to appeal.

Merck had filed infringement actions against Viatris under two patents, for which Viatris alleged non-infringement and, or invalidity, it said.

Viatris is seeking U.S. Food and Drug Administration approval to market generic versions of Januvia and Janumet in the U.S., Merck said.


Write to Sabela Ojea at


(END) Dow Jones Newswires

September 22, 2022 07:23 ET (11:23 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Jan 2023 to Feb 2023 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2022 to Feb 2023 Click Here for more Merck Charts.